Have you ever dreamed of achieving financial success by investing in penny stocks like Syncom Formulations Ltd? If the answer is yes, then this article is a must-read for you. We will take you on an enlightening journey as we conduct a fundamental analysis of Syncom Formulations (India), revealing the projected Syncom Formulations share price targets for the years 2024 to 2050.
In the dynamic realm of investments and stock markets, the quest for promising opportunities is ceaseless. Today, we extend an invitation to embark on an exhilarating exploration of Syncom Formulations, a pharmaceutical company that has been making waves in the market.
Our primary focus will be on analyzing their share price targets and delving into the prospects, predictions, and possibilities that lie ahead for investors. We will traverse the years 2024, 2025, 2030, and extend our gaze all the way to 2050. So, without any further delay, let us commence this captivating journey!
Trending Now – Suzlon Share Price Target | Indian Infotech Stock Target Price
About Syncom Formulations
Syncom Formulations (India) Limited is an Indian pharmaceutical company headquartered in Mumbai. The company’s primary focus is on manufacturing and marketing formulation products. Currently, Syncom operates in approximately 25 countries worldwide and has over 400 registered products.
Within Syncom Formulations, there is a domestic division called CRATUS. This division is responsible for manufacturing a variety of products, including tablets, capsules, ointments, injections, and more. The company is led by Mr. Kedarmal Shankarlal Bankda, who serves as the Chairman and Whole-Time Director, and Mr. Vijay Shankarlal Bankda, who is the Managing Director. Mr. Kedarmal Shankarlal Bankda is also the founder of Syncom Formulations (India) Limited and possesses extensive experience in the pharmaceutical industry.
Syncom Formulations Stock Fundamental Analysis
Data As of 27th December 2023
Current Market Price | Rs. 16.30 |
Market Cap | Rs. 1,534 Crores |
P/E Ratio | 66.5 |
EPS | 0.25 |
52 Week High | Rs. 16.5 |
52 Week Low | Rs. 4.55 |
Book Value | Rs. 2.87 |
Dividend Yield | 0% |
ROCE | 9.70% |
ROE | 8.42% |
Promoters Holding | 50.57% |
Public Holding | 49.44% |
Syncom Formulations’ sales growth has been modest, with a compounded sales growth rate of 7% over the past 5 and 10 years, 3% over the past 3 years, and 4% in the last year. However, the profit growth rate is slightly better, with a compound annual growth rate (CAGR) of 13% over 10 years, 18% over 5 years, 12% over 3 years, and 2% in the last year.
On the other hand, the stock price has shown significant fluctuations. The CAGR for stock prices has been 7% over 10 years, 48% over 5 years, 58% over 3 years, and -4% in the last year.
Syncom Formulations maintains a Debt to Equity ratio of 0.27, indicating a controlled level of debt. The company’s operating profit margin (OPM) stands at 9%, which is not particularly impressive. While there aren’t many significant concerns regarding the company, one point of concern is the intense competition from established players such as Laurus Labs, Ajanta Pharma, and Windlas Biotech, which poses a significant challenge to Syncom Formulations’ growth.
Syncom Formulations Share Price Target 2024 to 2050
One of the biggest mistakes that individual investors make in the stock market is having unrealistic expectations for penny stocks. They often believe that a stock priced at Rs. 10 can easily double in value with minimal risk, leading them to invest a large amount of money based on this flawed thinking. However, this approach is completely wrong.
When it comes to investing, it is crucial to rely on fundamental analysis. If a stock’s fundamentals are weak but its price remains high, there is a high likelihood of stock manipulation, especially in the case of penny stocks. Many small-cap penny stocks experience a “pump and dump” scheme, resulting in retail investors losing their money in such situations.
![Syncom Formulations share price target 2024 to 2050](https://sharekingz.com/wp-content/uploads/2023/08/syncom-formulations-share-price-target.jpg)
Therefore, it is advisable not to solely focus on predicting the price of Syncom Formulations. Instead, it is important to conduct a thorough analysis of the stock and the company’s fundamentals. We have provided the fundamental checks for Syncom Formulations below. However, before that, you can take a look at the projected stock price in the table provided.
Year | Syncom Formulations Stock Target Price |
2024 | Rs. 23 |
2025 | Rs. 30 |
2026 | Rs. 39 |
2027 | Rs. 43 |
2028 | Rs. 51 |
2029 | Rs. 68 |
2030 | Rs. 80 |
2031 | Rs. 95 |
2032 | Rs. 113 |
2033 | Rs. 125 |
2034 | Rs. 150 |
2035 | Rs. 163 |
2036 | Rs. 181 |
2037 | Rs. 205 |
2038 | Rs. 233 |
2039 | Rs. 298 |
2040 | Rs. 311 |
2041 | Rs. 337 |
2042 | Rs. 351 |
2043 | Rs. 375 |
2044 | Rs. 400 |
2045 | Rs. 429 |
2046 | Rs. 460 |
2047 | Rs. 489 |
2048 | Rs. 521 |
2049 | Rs. 601 |
2050 | Rs. 649 |
Factors Affecting Syncom Formulations Stock Price
The stock market is a dynamic entity influenced by various factors that can affect the price of a stock, including those pertaining to Syncom Formulations:
- The company’s market presence and its ability to launch strong products and effectively market them can give it a competitive advantage over established competitors. This, in turn, can have a positive impact on the company’s financials and subsequently on its share price.
- The overall trend within the pharmaceutical sector can also influence the stock price of Syncom Formulations. For instance, during the Covid-19 pandemic in 2020, pharmaceutical stocks experienced a significant surge in demand, leading to an increase in their share prices. If a similar trend occurs in the future, it could potentially drive up the share price of Syncom Formulations.
- The sentiments prevailing in both domestic and global markets can play a crucial role in impacting the price of Syncom Formulations’ stock. For example, during the recession concerns in 2022, many stocks faced pressure. Such sentiments can significantly influence the share price of Syncom Formulations.
- In addition to these factors, there are numerous other elements that can affect the stock price, including corporate actions, news related to the company, Syncom’s expansion plans, the launch of new products, and more. These factors should also be taken into consideration when assessing the potential impact on the share price.
Also Read: IRFC Stock Target Price | Shalimar Production Share Target
Investors’ FAQs Related to Syncom Formulations Share Target
Is Syncom Formulations a multibagger?
In the world of equity markets, nothing is guaranteed, and Syncom is considered a small-cap company with a market capitalization of Rs. 724 Crores. Investing in such small-cap stocks can carry inherent risks, as they are more susceptible to manipulation by stock operators. Therefore, it is crucial to prioritize risk management.
We strongly advise conducting a thorough analysis before considering an investment in this particular stock. While there is potential for it to become a high-growth investment (a “multibagger”) in the future if the company performs well, this outcome is not guaranteed at the present moment.
Conclusion
Syncom Formulations appears to be a decent company with a limited number of concerning factors. However, due to its small market capitalization, there is a potential risk of stock manipulation. Therefore, it is crucial for investors to prioritize risk management. If you have any questions, please feel free to leave them in the comments section below. Our team of experts will be more than happy to assist you.
Disclaimer: The information provided is intended for educational purposes only. We do not provide any recommendations for trading or investing.
Leave a Reply